Norman D. Schwartz - 05 Sep 2025 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role: Chairman & CEO, Director, 10%+ Owner
Signature: /s/ Norman Schwartz
Issuer symbol: BIO
Transactions as of: 05 Sep 2025
Net transactions value: -$451,417
Form type: 4
Filing time: 09 Sep 2025, 16:19:59 UTC
Previous filing: 03 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SCHWARTZ NORMAN D	Chairman & CEO, Director, 10%+ Owner	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES	/s/ Norman Schwartz	09 Sep 2025	0000940805

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIO BIO.B	Bio-Rad A Common Stock	Options Exercise	$0	+3,455	+0.78%	$0.000000	444,962	06 Sep 2025	Direct	F1
transaction	BIO BIO.B	Bio-Rad A Common Stock	Tax liability	$451,417	-1,528	-0.34%	$295.43	443,434	06 Sep 2025	Direct
holding	BIO BIO.B	Bio-Rad B Common Stock						361,466	05 Sep 2025	Direct
holding	BIO BIO.B	Bio-Rad B Common Stock						13,006	05 Sep 2025	By Spouse	F2
holding	BIO BIO.B	Bio-Rad B Common Stock						4,060,054	05 Sep 2025	By Blue Raven Partners, L.P.	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIO BIO.B	Restricted Stock Units	Award	$0	+16,439		$0.000000	16,439	05 Sep 2025	Bio-Rad A Common Stock	16,439	$0.000000	Direct	F4, F5
transaction	BIO BIO.B	Restricted Stock Units	Options Exercise	$0	-3,455	-25%	$0.000000	10,367	06 Sep 2025	Bio-Rad A Common Stock	3,455	$0.000000	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of Class A common stock acquired on the vesting of restricted stock units.
F2	The reporting person disclaims beneficial ownership of these shares.
F3	The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4	Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F5	The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.